In the Media: Esketamine Effective and Costly Treating Treatment-Resistant Depression
HCP Live
Dr. Eric L. Ross and collaborators examine the cost-effectiveness of esketamine, a novel intranasally dosed antidepressant for patients with treatment-resistant depression.
Media Requests
Journalist or member of the media?
We are available 24/7 for media requests.
